Compositions and methods for targeting cancer cells

Details Compositions and methods for targeting cancer cells Compositions and methods for targeting cancer cells

2007-12-18

2007-12-18

Lewis, Patrick (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S043000, C514S049000, C514S050000

Reexamination Certificate

active

10748738

ABSTRACT:
The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds which comprise an alkyl lipid or phospholipid moiety covalently conjugated with an anticancer agent (e.g. a nucleoside analogue). The invention also includes pharmaceutical compositions and kits for combating a cancer and for facilitating delivery of a therapeutic agent to a mammalian cell. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to combat a cancer or to facilitate delivery of a therapeutic agent to a mammalian cell.

REFERENCES:
patent: 2086585 (1937-07-01), Taub et al.
patent: 2087132 (1937-07-01), Taub et al.
patent: 2108765 (1938-02-01), Domagk
patent: 2209383 (1940-07-01), Bock
patent: 2439969 (1948-04-01), Fourneau
patent: 2445393 (1948-07-01), Fourneau
patent: 2513747 (1950-07-01), Sallman et al.
patent: 2606909 (1952-08-01), Blicke
patent: 2689790 (1954-09-01), Mowry et al.
patent: 2950253 (1960-08-01), Kling et al.
patent: 3054678 (1962-09-01), Michener et al.
patent: 3694473 (1972-09-01), Eibl et al.
patent: 4093714 (1978-06-01), Tolman et al.
patent: 4096278 (1978-06-01), Queuille
patent: 4119714 (1978-10-01), Kny et al.
patent: 4159988 (1979-07-01), Eibl et al.
patent: 4221732 (1980-09-01), Oette et al.
patent: 4235877 (1980-11-01), Fullerton
patent: 4291024 (1981-09-01), Turcotte
patent: 4329302 (1982-05-01), Hanahan et al.
patent: 4426525 (1984-01-01), Hozumi et al.
patent: 4444766 (1984-04-01), Bosies et al.
patent: 4471113 (1984-09-01), MacCoss
patent: 4540521 (1985-09-01), Garst et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4619917 (1986-10-01), Lee et al.
patent: 4622392 (1986-11-01), Hong et al.
patent: 4661509 (1987-04-01), Gordon et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4797479 (1989-01-01), Shuto et al.
patent: 4816450 (1989-03-01), Bell et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4826823 (1989-05-01), Cook et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4837023 (1989-06-01), Eibl
patent: 4841039 (1989-06-01), Chu et al.
patent: 4880782 (1989-11-01), Eckstein et al.
patent: 4921951 (1990-05-01), Shuto et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 4997761 (1991-03-01), Jett-Tilton
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5034394 (1991-07-01), Daluge
patent: 5138045 (1992-08-01), Cook et al.
patent: 5221696 (1993-06-01), Ke et al.
patent: 5496546 (1996-03-01), Wang et al.
patent: 5512671 (1996-04-01), Piantadosi
patent: 5614548 (1997-03-01), Piantadosi et al.
patent: 5633388 (1997-05-01), Diana et al.
patent: 5770584 (1998-06-01), Kucera et al.
patent: 5830905 (1998-11-01), Diana et al.
patent: 5846964 (1998-12-01), Ozeki
patent: 5891874 (1999-04-01), Colacino et al.
patent: 5922757 (1999-07-01), Chojkier
patent: 5962437 (1999-10-01), Kucera et al.
patent: 5985854 (1999-11-01), Kozak
patent: 6030960 (2000-02-01), Morris-Natschke et al.
patent: 6077837 (2000-06-01), Kozak
patent: 6136796 (2000-10-01), Kozak
patent: 6166089 (2000-12-01), Kozak
patent: 6670341 (2003-12-01), Kucera et al.
patent: 37 26 945 (1989-02-01), None
patent: 39 34 820 (1991-04-01), None
patent: 40 10 228 (1991-10-01), None
patent: 199 14 474 (1999-10-01), None
patent: 0 094 586 (1983-11-01), None
patent: 0 109 255 (1984-05-01), None
patent: 0 142 333 (1985-05-01), None
patent: 0 145 303 (1985-06-01), None
patent: 0 146 258 (1985-06-01), None
patent: 0 252 310 (1988-01-01), None
patent: 0 310 109 (1989-04-01), None
patent: 0 335 396 (1989-04-01), None
patent: 0 348 859 (1990-01-01), None
patent: 0 350 287 (1990-01-01), None
patent: 0 416 401 (1991-03-01), None
patent: 0 434 450 (1991-06-01), None
patent: 0 506 704 (1991-07-01), None
patent: 0 632 048 (1995-01-01), None
patent: 1561630 (1969-03-01), None
patent: 2 239 243 (1991-06-01), None
patent: 42-13841 (1967-08-01), None
patent: 49-100224 (1974-09-01), None
patent: 61-238793 (1986-10-01), None
patent: 1029312 (1989-01-01), None
patent: 08-268890 (1996-10-01), None
patent: 10-10591 (1998-04-01), None
patent: 90/00555 (1990-01-01), None
patent: 90/05736 (1990-05-01), None
patent: 90/15601 (1990-12-01), None
patent: 91/05558 (1991-05-01), None
patent: 91/09602 (1991-07-01), None
patent: 91/18914 (1991-12-01), None
patent: 91/19726 (1991-12-01), None
patent: 92/03462 (1992-03-01), None
patent: 92/06192 (1992-04-01), None
patent: 93/00910 (1993-01-01), None
patent: 93/08807 (1993-05-01), None
patent: 93/16091 (1993-08-01), None
patent: 93/16092 (1993-08-01), None
patent: 93/17020 (1993-09-01), None
patent: 93/21191 (1993-10-01), None
patent: WO 94/28908 (1994-12-01), None
patent: WO 96/06620 (1996-03-01), None
patent: WO 96/25147 (1996-08-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 01/19320 (2001-03-01), None
patent: WO 01/34614 (2001-05-01), None
Aggarwal, S.K. et al., “Synthesis and Biological Evaluation of Prodrugs of Zidovudine,”J. Med. Chem., 33, 1505-10, 1990.
Alt M. et al., “Core Specific Antisense Phosphorthioate Oligodeoxynucleotides as Potent and Specific Inhibitors of Hepatitis C Viral Translation,”Archives of Virology142:589-599, 1997.
Alt M. et al., “Specific Inhibition of Hepatitis C Viral Gene Expression by Antisense Phosphorothioate Oligodeoxynucleotides,”Hepatology22:707-717, Sep. 1995.
Amari et al., “Isolation of Experimental Anti-AIDS Glycerophospholipids by Micro-Preparative Reversed-Phase High-Performance Liquid Chromatography,”Journal of Chromatography, 590, 153-161, 1992.
Anderson, L. J. et al., “Antigenic Characterization of Respiratory Syncytial Virus Strains with Monoclonal Antibodies,”Journal of Infectious Diseases, 151:626-633, Apr. 1985.
Attwood, M. R. et al., “The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase,”Antiviral Chemistry and Chemotherapy10:259-273, Sep. 1999.
Bartlett,Infectious Diseases in Clinical Practice, 5:172-179, 1996.
Berdel et al., “Cyto Toxicity of Thio Ether Lyso Phospho Lipids in Leukemias and Tumors of Human Origin,”Cancer Research, vol. 43, 5538-5543, 1983.
Berenguer, M. et al., “Hepatitis C Virus in the Transplant Setting,”Antiviral Therapy3(Suppl. 3):125-136, 1998.
Boldanova, N. B. et al., “Protective Effect of Phosphatidylcholine-Containing Liposomes in Experimental Toxic Hepatitis,”Vopr. Med. Khim, 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract No. 35587k (1986).
Bosies, E. et al., “Preparation of Lecithin Analogs as Retrovirucides and Virucides,”Chemical Abstracts, 115CA; 72142p, 1991.
Braekman et al.,Proc. Amer. Soc. for Clinical Oncology, Abstract # 810, 1997.
Capizzi, Investigational New Drugs 14: 249-256, 1996.
Chen, “Design and Synthesis of Novel Nucleoside Analogs as Potential Antiviral Agents,” AbstractAmerican Assoc. of Ph

Affiliated with

Also associated with

Rating

Compositions and methods for targeting cancer cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for targeting cancer cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for targeting cancer cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3885084